{Reference Type}: Clinical Trial, Phase III
{Title}: Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC).
{Author}: Sato Y;Yamada T;Yoshikawa T;Machida R;Mizusawa J;Katayama H;Tokunaga M;Boku N;Terashima M; ;
{Journal}: Jpn J Clin Oncol
{Volume}: 50
{Issue}: 11
{Year}: Oct 2020 22
{Factor}: 2.925
{DOI}: 10.1093/jjco/hyaa113
{Abstract}: Gastrectomy with omentectomy and D2 lymph node dissection is the current standard procedure for locally advanced gastric cancer. However, some retrospective studies have reported that omentectomy increased post-operative abdominal complications but provided no survival advantage over omentum preservation. Therefore, we plan a randomized controlled phase III trial to confirm the non-inferiority of omentum preservation compared with omentectomy in patients with cT3 (SS) or cT4a (SE) gastric cancer. A total of 1050 patients will be enrolled from 62 institutions over a period of 6.5 years. The primary end point is relapse-free survival, and the secondary end points are overall survival, blood loss, operation time and adverse events. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000036253.